T. Rowe Price Associates
LAB icon

T. Rowe Price Associates’s Standard BioTools LAB Stock Holding History

T. Rowe Price Associates’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$187K Buy
202,466
+30,332
+18% +$36.7K ﹤0.01% 2865
2025
Q4 		$221K Buy
172,134
+14,592
+9% +$19.6K ﹤0.01% 2778
2025
Q3 		$205K Sell
157,542
-52,119
-25% -$68.3K ﹤0.01% 2786
2025
Q2 		$252K Buy
209,661
+14,193
+7% +$15.7K ﹤0.01% 2606
2025
Q1 		$212K Buy
195,468
+14,000
+8% +$19.7K ﹤0.01% 2609
2024
Q4 		$318K Buy
181,468
+16,475
+10% +$30.7K ﹤0.01% 2485
2024
Q3 		$319K Sell
164,993
-50
-0% -$98 ﹤0.01% 2449
2024
Q2 		$293K Buy
165,043
+96,174
+140% +$235K ﹤0.01% 2424
2024
Q1 		$187K Buy
68,869
+42,069
+157% +$102K ﹤0.01% 2641
2023
Q4 		$60K Sell
26,800
-11,600
-30% -$24.8K ﹤0.01% 2781
2023
Q3 		$112K Hold
38,400
– – ﹤0.01% 2639
2023
Q2 		$75K Sell
38,400
-12,300
-24% -$24.3K ﹤0.01% 2745
2023
Q1 		$99K Sell
50,700
-34,200
-40% -$67.6K ﹤0.01% 2690
2022
Q4 		$99K Buy
84,900
+23,100
+37% +$28.4K ﹤0.01% 2722
2022
Q3 		$68K Buy
61,800
+44,100
+249% +$66.7K ﹤0.01% 2790
2022
Q2 		$28K Sell
17,700
-6,961
-28% -$17.2K ﹤0.01% 2913
2022
Q1 		$89K Buy
24,661
+1,900
+8% +$6.56K ﹤0.01% 2867
2021
Q4 		$89K Sell
22,761
-28,300
-55% -$132K ﹤0.01% 2888
2021
Q3 		$336K Sell
51,061
-7,781
-13% -$51.2K ﹤0.01% 2539
2021
Q2 		$362K Buy
58,842
+1,970
+3% +$10.5K ﹤0.01% 2524
2021
Q1 		$257K Sell
56,872
-19,845
-26% -$109K ﹤0.01% 2613
2020
Q4 		$460K Buy
76,717
+43,800
+133% +$288K ﹤0.01% 2275
2020
Q3 		$245K Buy
+32,917
New +$227K ﹤0.01% 2364
2017
Q4 		– Sell
-14,900
Closed -$75K – 2592
2017
Q3 		$75K Hold
14,900
– – ﹤0.01% 2527
2017
Q2 		$60K Hold
14,900
– – ﹤0.01% 2519
2017
Q1 		$85K Hold
14,900
– – ﹤0.01% 2506
2016
Q4 		$108K Hold
14,900
– – ﹤0.01% 2463
2016
Q3 		$119K Sell
14,900
-8,100
-35% -$74.4K ﹤0.01% 2424
2016
Q2 		$208K Hold
23,000
– – ﹤0.01% 2311
2016
Q1 		$186K Hold
23,000
– – ﹤0.01% 2306
2015
Q4 		$249K Buy
+23,000
New +$226K ﹤0.01% 2222

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

T. Rowe Price Associates's LAB Position: Q1 2026 in Review

T. Rowe Price Associates increased its Standard BioTools (LAB) stake by 18% in Q1 2026, buying an estimated $36.7K and bringing the position to 202,466 shares worth $187K. The position accounts for ﹤0.01% of the portfolio, ranked #2865.

T. Rowe Price Associates first reported a position in LAB in Q4 2015 and has held it in 31 quarters since. The position peaked at $460K in Q4 2020. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

  • T. Rowe Price Associates held 202,466 shares of Standard BioTools worth $187K as of Q1 2026.
  • T. Rowe Price Associates bought 30,332 Standard BioTools shares in Q1 2026, an estimated $36.7K.
  • Standard BioTools made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2865 holding.
  • T. Rowe Price Associates first reported a position in Standard BioTools in Q4 2015 and has held it in 31 quarters since.
  • T. Rowe Price Associates's Standard BioTools position peaked at $460K in Q4 2020.
  • 155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.